KalshiComprobar disponibilidadKYC requeridoDatos de resolución verificadosBien calibradoPunto medio del libro seleccionado
No · —
Cargando el libro seleccionado…
—
Precio guardado
No 84%
No 84%Calidad del mercado
70 / 100
Calidad mediaVolumen 24h
116,8 €
Interés abierto
94,9 mil US$
Interés abierto altoCompra / Venta
— / —
NoSpread
—
Datos de mercado
Actualizado hace 16 minutos
17 jul 25, 14:00 UTC1 ene 27, 4:59 UTC
El gráfico y los cambios muestran probabilidades históricas guardadas, no el libro seleccionado en directo.
Tendencias
Fila seleccionada: punto medio del libro. Otras filas: referencias guardadas, posiblemente normalizadas; los cambios de 24h usan el historial guardado.
Condiciones de la plataforma
Fuente: Kalshi
Estas condiciones son informativas; las operaciones simuladas de CoinRithm siguen sus propias reglas.
- Cierre anticipado:
- Sí
- Plazo de liquidación:
- 30m (informativo)
Profundidad de mercado · No
Cargando el libro seleccionado…
—
Mercados Relacionados
Preguntas relacionadas para dar contexto, no una comparación de contratos equivalentes.
Will the FDA approve any psychedelic substance for medical use before 2028?
KalshiWill the FDA approve a psychedelic-assisted therapy for a mental disorder by 2027?
Manifold MarketsWill a psychedelic substance get de-scheduled by the US by 2030?
Manifold MarketsWill the FDA approve retatrutide?
KalshiWill the FDA approve cytisinicline for smoking cessation?
KalshiWhen will the FDA approve Compass Pathways' COMP360 Psilocybin?
KalshiReglas
La regla exacta de este resultado no está disponible.
- Psychedelic drugs include: LSD, Psilocybin, DMT, Mescaline, MDMA, MDA, PCP, DXM, Ibogaine, Salvia divinorum, 2C family, and Ayahuasca. Important information: For purposes of this Contract: The listed substances are illustrative, not exhaustive. Approval of any other substance commonly recognized in scientific or FDA documentation as a psychedelic, hallucinogen, or entactogen (for example, psilocin, 5-MeO-DMT, methylone, or 2C-, DOx-, or NBOMe-family compounds) may also satisfy the Payout Criterion. "Approval for medical use" means an FDA approval letter for an NDA or BLA authorizing marketing of a drug or biologic for human medical use in the United States, where a listed (or otherwise qualifying) psychedelic substance is an active pharmaceutical ingredient of the approved product. Complete Response Letters, tentative approvals, Emergency Use Authorizations, expanded access or compassionate use authorizations, and approvals limited to export do not satisfy the Payout Criterion. Combination products. Approval of a combination drug product satisfies the Payout Criterion only if at least one active ingredient is a listed (or otherwise qualifying) psychedelic substance and that psychedelic active ingredient has not previously been approved by the FDA via NDA or BLA for any human medical indication. By way of example, an FDA approval of AXS-05 (a combination of dextromethorphan and bupropion) for a new indication does not satisfy the Payout Criterion, because both active ingredients were FDA-approved prior to Issuance. New indications for previously-approved substances. An FDA approval (including via supplemental NDA or supplemental BLA) of a new medical indication, dosage, or formulation for a substance whose active pharmaceutical ingredient was already approved by the FDA via NDA or BLA prior to Issuance does not satisfy the Payout Criterion.
Reglas de cada resultado
- No
- La regla exacta de este resultado no está disponible.
- Yes
- La regla exacta de este resultado no está disponible.
